Soluble immune checkpoints and T-cell subsets in blood as biomarkers for resistance to immunotherapy in melanoma patients

Different mechanisms lead to immune checkpoint inhibitor (ICI) resistance. Identifying clinically useful biomarkers might improve drug selection and patients’ therapy. We analyzed the soluble immune checkpoints sPD1, sPDL1, sLAG3, and sTIM3 using ELISA and their expression on circulating T cells usi...

Descrición completa

Detalles Bibliográficos

Principais autores:	Devayani Machiraju, Melanie Wiecken, Nina Lang, Ingrid Hülsmeyer, Jasmin Roth, Timo E. Schank, Rosa Eurich, Niels Halama, Alexander Enk, Jessica C. Hassel
Formato:	Artigo
Idioma:	Inglês
Publicado:	Taylor & Francis Group 2021-01-01
Series:	OncoImmunology
Assuntos:	melanoma immune checkpoints immunotherapy t lymphocytes
Acceso en liña:	http://dx.doi.org/10.1080/2162402X.2021.1926762
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!